Zura Bio Limited Class A Ordinary Shares Total Liabilities
Zura Bio Limited Class A Ordinary Shares total liabilities. Based on the latest financial reports, Zura Bio Limited Class A Ordinary Shares (ZURA) has total liabilities worth $25.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Zura Bio Limited Class A Ordinary Shares liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Zura Bio Limited Class A Ordinary Shares (2021–2024)
Total liabilities of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024. This chart illustrates how Zura Bio Limited Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data.
Zura Bio Limited Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Zura Bio Limited Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fagerhult AB
ST:FAG
|
Sweden | Skr6.56 Billion |
|
G1 Secure Solutions Ltd
TA:GOSS
|
Israel | ILA510.23 Million |
|
Aviat Networks Inc
NASDAQ:AVNW
|
USA | $331.57 Million |
|
Newron Pharmaceuticals SpA
SW:NWRN
|
Switzerland | CHF51.15 Million |
|
Secuoya Grupo de Comunicación S.A
MC:SEC
|
Spain | €151.29 Million |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
USA | $6.38 Million |
|
Highview Merger Corp. Class A Ordinary Share
NASDAQ:HVMC
|
USA | $242.98 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
China | CN¥139.62 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Zura Bio Limited Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Zura Bio Limited Class A Ordinary Shares.
Liquidity & Leverage Metrics
Zura Bio Limited Class A Ordinary Shares Total Liabilities Ratios Explained
Zura Bio Limited Class A Ordinary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zura Bio Limited Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zura Bio Limited Class A Ordinary Shares (2021–2024)
The table below shows the annual total liabilities of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.51 Million | -8.35% |
| 2023-12-31 | $21.29 Million | -22.06% |
| 2022-12-31 | $27.32 Million | +163.89% |
| 2021-12-31 | $10.35 Million | -- |
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more